Pharmacokinetic and pharmacodynamic properties of carvedilol in fructose hypertensive rats

References

• Aimone LD. (2005). Overview of pharmacokinetics. Curr Protoc Pharmacol 7.1:1–26.
   Google Scholar
• Alberti KG, Zimmet P, Shaw J. (2006). Metabolic syndrome–a new world-wide definition. A Consensus Statement from the International Diabetes Federation. Diabet Med 23:469–480.
   PubMed Web of Science ®Google Scholar
• Bartsch W, Sponer G, Strein K, Müller-Beckmann B, Kling L, Böhm E, Martin U, Borbe HO. (1990). Pharmacological characteristics of the stereoisomers of carvedilol. Eur J Clin Pharmacol 38 Suppl 2:S104–S107.
   Google Scholar
• Bertera FM, Di Verniero CA, Mayer MA, Bramuglia GF, Taira CA, Höcht C. (2009). Is urethane-chloralose anaesthesia appropriate for pharmacokinetic-pharmacodynamic assessment? Studies with carvedilol. J Pharmacol Toxicol Methods 59:13–20.
   PubMedGoogle Scholar
• Bertera FM, Mayer MA, Opezzo JA, Taira CA, Höcht C. (2009). Increased sensitivity to diltiazem hypotensive effect in an experimental model of high-renin hypertension. J Pharm Pharmacol 61:79–87.
   PubMed Web of Science ®Google Scholar
• Carella AM, Antonucci G, Conte M, Di Pumpo M, Giancola A, Antonucci E. (2010). Antihypertensive treatment with beta-blockers in the metabolic syndrome: a review. Curr Diabetes Rev 6:215–221.
   PubMedGoogle Scholar
• Catena C, Giacchetti G, Novello M, Colussi G, Cavarape A, Sechi LA. (2003). Cellular mechanisms of insulin resistance in rats with fructose-induced hypertension. Am J Hypertens 16:973–978.
   PubMed Web of Science ®Google Scholar
• D’Argenio DZ, Schumitzky A. (1997). ADAPT II User’s Guide: Pharmacokinetic/Pharmacodynamic Systems Analysis Software. Los Angeles: Biomedical Simulations Resource.
   Google Scholar
• Di Verniero CA, Bertera F, Buontempo F, Bernabeu E, Chiappetta D, Mayer MA, Bramuglia GF, Taira CA, Höcht C. (2010). Enantioselective pharmacokinetic-pharmacodynamic modelling of carvedilol in a N-nitro-l-arginine methyl ester rat model of secondary hypertension. J Pharm Pharmacol 62:890–900.
   PubMed Web of Science ®Google Scholar
• Di Verniero CA, Silberman EA, Mayer MA, Opezzo JA, Taira CA, Höcht C. (2008). In vitro and in vivo pharmacodynamic properties of metoprolol in fructose-fed hypertensive rats. J Cardiovasc Pharmacol 51:532–541.
   PubMed Web of Science ®Google Scholar
• Fazan R Jr, Huber DA, Silva CA, Dias da Silva VJ, Salgado MC, Salgado HC. (2008). Sildenafil acts on the central nervous system increasing sympathetic activity. J Appl Physiol 104:1683–1689.
   PubMedGoogle Scholar
• Frishman WH. (1998). Carvedilol. N Engl J Med 339:1759–1765.
   PubMed Web of Science ®Google Scholar
• Fujimaki M. (1992). Stereoselective disposition and tissue distribution of carvedilol enantiomers in rats. Chirality 4:148–154.
   PubMedGoogle Scholar
• Gibaldi M, Perrier D. (1982). Pharmacokinetics, 2nd edn. New York: Marcel Dekker.
   Google Scholar
• Grassi G, Dell’Oro R, Facchini A, Quarti Trevano F, Bolla GB, Mancia G. (2004). Effect of central and peripheral body fat distribution on sympathetic and baroreflex function in obese normotensives. J Hypertens 22:2363–2369.
   PubMed Web of Science ®Google Scholar
• Grassi G, Seravalle G. (2006). Autonomic imbalance and metabolic syndrome: unravelling interactions, mechanisms and outcomes. J Hypertens 24:47–49.
   PubMed Web of Science ®Google Scholar
• Grassi G. (1998). Role of the sympathetic nervous system in human hypertension. J Hypertens 16:1979–1987.
   PubMed Web of Science ®Google Scholar
• Höcht C, Bertera FM, Taira CA. (2010). Importance of blood pressure variability in the assessment of cardiovascular risk and benefits of antihypertensive therapy. Exp Rev Clin Pharmacol 3:617–621.
   PubMedGoogle Scholar
• Höcht C, Mayer MA, Opezzo JAW, Bertera FM, Taira CA. (2008). Pharmacokinetic-pharmacodynamic modeling of antihypertensive drugs: from basic research to clinical practice. Curr Hypertens Rev 4:289–302.
   Google Scholar
• Hsieh PS. (2005). Reversal of fructose-induced hypertension and insulin resistance by chronic losartan treatment is independent of AT2 receptor activation in rats. J Hypertens 23:2209–2217.
   PubMedGoogle Scholar
• Hwang IS, Huang WC, Wu JN, Shian LR, Reaven GM. (1989). Effect of fructose-induced hypertension on the renin-angiotensin-aldosterone system and atrial natriuretic factor. Am J Hypertens 2:424–427.
   PubMed Web of Science ®Google Scholar
• Hwang IS, Ho H, Hoffman BB, Reaven GM. (1987). Fructose-induced insulin resistance and hypertension in rats. Hypertension 10:512–516.
   PubMed Web of Science ®Google Scholar
• Ishida K, Taira S, Morishita H, Kayano Y, Taguchi M, Hashimoto Y. (2008). Stereoselective oxidation and glucuronidation of carvedilol in human liver and intestinal microsomes. Biol Pharm Bull 31:1297–1300.
   PubMed Web of Science ®Google Scholar
• Kamide K, Rakugi H, Higaki J, Okamura A, Nagai M, Moriguchi K, Ohishi M, Satoh N, Tuck ML, Ogihara T. (2002). The renin-angiotensin and adrenergic nervous system in cardiac hypertrophy in fructose-fed rats. Am J Hypertens 15:66–71.
   PubMedGoogle Scholar
• Keating GM, Jarvis B. (2003). Carvedilol: a review of its use in chronic heart failure. Drugs 63:1697–1741.
   PubMed Web of Science ®Google Scholar
• Louis WJ, McNeil JJ, Workman BS, Drummer OH, Conway EL. (1987). A pharmacokinetic study of carvedilol (BM 14.190) in elderly subjects: preliminary report. J Cardiovasc Pharmacol 10 Suppl 11:S89–S93.
   Google Scholar
• Mayer MA, Höcht C, Gironacci M, Opezzo JA, Taira CA, Fernández BE, Puyó AM. (2008). Hypothalamic angiotensinergic-noradrenergic systems interaction in fructose induced hypertension. Regul Pept 146:38–45.
   PubMedGoogle Scholar
• Mayer MA, Höcht C, Opezzo JA, Taira CA, Fernández BE, Puyó AM. (2007). High fructose diet increases anterior hypothalamic alpha 2-adrenoceptors responsiveness. Neurosci Lett 423:128–132.
   PubMedGoogle Scholar
• Neugebauer G, Akpan W, Kaufmann B, Reiff K. (1990). Stereoselective disposition of carvedilol in man after intravenous and oral administration of the racemic compound. Eur J Clin Pharmacol 38 Suppl 2:S108–S111.
   PubMedGoogle Scholar
• Phuong NT, Lee BJ, Choi JK, Kang JS, Kwon KI. (2004). Enantioselective pharmacokinetics of carvedilol in human volunteers. Arch Pharm Res 27:973–977.
   PubMedGoogle Scholar
• Pikkujämsä SM, Huikuri HV, Airaksinen KE, Rantala AO, Kauma H, Lilja M, Savolainen MJ, Kesäniemi YA. (1998). Heart rate variability and baroreflex sensitivity in hypertensive subjects with and without metabolic features of insulin resistance syndrome. Am J Hypertens 11:523–531.
   PubMed Web of Science ®Google Scholar
• Pladys P, Lahaie I, Cambonie G, Thibault G, Lê NL, Abran D, Nuyt AM. (2004). Role of brain and peripheral angiotensin II in hypertension and altered arterial baroreflex programmed during fetal life in rat. Pediatr Res 55:1042–1049.
   PubMedGoogle Scholar
• Ponchon P, Elghozi JL. (1997). Contribution of humoral systems to the short-term variability of blood pressure after severe hemorrhage. Am J Physiol 273:R58–R69.
   PubMed Web of Science ®Google Scholar
• Prakash AK, Kumar A. (2009). Effect of chronic treatment of carvedilol on oxidative stress in an intracerebroventricular streptozotocin induced model of dementia in rats. J Pharm Pharmacol 61:1665–1672.
   PubMedGoogle Scholar
• Ruffolo RR Jr, Gellai M, Hieble JP, Willette RN, Nichols AJ. (1990). The pharmacology of carvedilol. Eur J Clin Pharmacol 38 Suppl 2:S82–S88.
   Google Scholar
• Souza HC, Martins-Pinge MC, Dias da Silva VJ, Borghi-Silva A, Gastaldi AC, Blanco JH, Tezini GC. (2008). Heart rate and arterial pressure variability in the experimental renovascular hypertension model in rats. Auton Neurosci 139:38–45.
   PubMed Web of Science ®Google Scholar
• Stahl E, Henke D, Mutschler E, Spahn-Langguth H. (1993). Saturable enantioselective first-pass effect for carvedilol after high oral racemate doses in rats. Arch Pharm (Weinheim) 326:123–125.
   PubMed Web of Science ®Google Scholar
• Stahl E, Mutschler E, Baumgartner U, Spahn-Langguth H. (1993). Carvedilol stereopharmacokinetics in rats: affinities to blood constituents and tissues. Arch Pharm (Weinheim) 326:529–533.
   PubMedGoogle Scholar
• Stauss HM. (2007). Identification of blood pressure control mechanisms by power spectral analysis. Clin Exp Pharmacol Physiol 34:362–368.
   PubMed Web of Science ®Google Scholar
• Su DF, Miao CY. (2005). Reduction of blood pressure variability: a new strategy for the treatment of hypertension. Trends Pharmacol Sci 26:388–390.
   PubMedGoogle Scholar
• Tentolouris N, Argyrakopoulou G, Katsilambros N. (2008). Perturbed autonomic nervous system function in metabolic syndrome. Neuromolecular Med 10:169–178.
   PubMed Web of Science ®Google Scholar
• Terao N, Shen DD. (1983). Alterations in serum protein binding and pharmacokinetics of l-propranolol in the rat elicited by the presence of an indwelling venous catheter. J Pharmacol Exp Ther 227:369–375.
   PubMedGoogle Scholar
• Tran LT, Yuen VG, McNeill JH. (2009). The fructose-fed rat: a review on the mechanisms of fructose-induced insulin resistance and hypertension. Mol Cell Biochem 332:145–159.
   PubMed Web of Science ®Google Scholar
• Verbeeck RK. (2008). Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction. Eur J Clin Pharmacol 64:1147–1161.
   PubMed Web of Science ®Google Scholar
• Verma S, Bhanot S, McNeill JH. (1999). Sympathectomy prevents fructose-induced hyperinsulinemia and hypertension. Eur J Pharmacol 373:R1–R4.
   PubMedGoogle Scholar
• Zhou HH, Wood AJ. (1995). Stereoselective disposition of carvedilol is determined by CYP2D6. Clin Pharmacol Ther 57:518–524.
   PubMed Web of Science ®Google Scholar